Iovance and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis, a clinical-stage biopharmaceutical company focused on…
Read More...
Read More...
